SGLT2 inhibitors reduce acute kidney injury incidence in patients with diabetes mellitus receiving cisplatin chemotherapy
In a retrospective study of 288 patients with diabetes mellitus receiving cisplatin, those taking SGLT2 inhibitors had a significantly lower incidence of acute kidney injury (13.9% vs 28.5%, OR 0.42, 95% CI 0.23-0.76). The SGLT2 inhibitor group also showed higher eGFR at 3 months and lower rates of hypomagnesemia and anemia.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
SGLT2 inhibitors reduce acute kidney injury incidence in patients with diabetes mellitus receiving cisplatin chemotherapy The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).
The Claim
SGLT2 inhibitors reduce acute kidney injury incidence in patients with diabetes mellitus receiving cisplatin chemotherapy
This conclusion is most relevant to: Patients with cancer and diabetes mellitus receiving intravenous cisplatin.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus. (Kidney international reports, 2026) —
How It Works
The proposed biological pathway:
- ▸SGLT2 inhibitors reduce tubular cell uptake of cisplatin
- ▸Decreased cisplatin accumulation in renal tubular cells
- ▸Reduced tubular cell injury and apoptosis
- ▸Result: Lower incidence of acute kidney injury
Who Might Benefit
Evidence fit by population:
- ▸Patients with cancer and diabetes mellitus receiving intravenous cisplatin
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Retrospective single-center study design limits causal inference
- ▸Potential residual confounding despite propensity score matching
- ▸Short median follow-up of 2 months may miss longer-term renal outcomes
Frequently Asked Questions
What is the main finding of this study?▼
SGLT2 inhibitor use was associated with a 58% reduction in the odds of acute kidney injury in patients with diabetes receiving cisplatin chemotherapy.
How was acute kidney injury defined in this study?▼
AKI was defined as a ≥50% increase in serum creatinine within 4 weeks of cisplatin administration.
What other benefits were observed in the SGLT2 inhibitor group?▼
The SGLT2 inhibitor group had higher eGFR at 3 months and lower rates of hypomagnesemia and anemia, though the difference in hyponatremia was not statistically significant.
What type of study was this?▼
This was a single-center retrospective observational study with propensity score matching, not a randomized controlled trial.
References
- 1.Cintrón-García JJ, Patel M, Andersen CR, Page V, Workeneh B, Mandayam S, Al-Dallal R, Abudayyeh A, Mamlouk O. “Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus..” Kidney international reports, 2026. PMID: 42179813 DOI: 10.1016/j.ekir.2026.106538